Science 4 Innovation Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science 4 Innovation Spółka Z Ograniczoną OdpowiedzialnościąfiledCriticalScience 4 Innovation Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL426567ApriorityCriticalpatent/PL426567A1/en
Publication of PL426567A1publicationCriticalpatent/PL426567A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Przedmiotem zgłoszenia jest opatrunek medyczny kolagenowo-grafenowy zawierający kolagen i tlenek grafenu. Opatrunek medyczny charakteryzuje się tym, że zawiera od 10 do 500 mg kolagenu i od 5 mg do 50 mg tlenku grafenu w dwóch postaciach. Kolagen zmieszany z tlenkiem grafenu i tlenek grafenu napylony na kolagen.The subject of the notification is a collagen-graphene medical dressing containing collagen and graphene oxide. The medical dressing is characterized by containing from 10 to 500 mg of collagen and from 5 mg to 50 mg of graphene oxide in two forms. Collagen mixed with graphene oxide and graphene oxide sprayed on collagen.
PL426567A2018-08-062018-08-06Collagen-graphene medical dressing
PL426567A1
(en)
POLYPEPTIDE OF SOLUBLE RECEPTOR 3 FIBROBAL GROWTH FACTOR (FGR3) FOR APPLICATION FOR THE PURPOSE OF PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH DECOMPOSITION OF SKELETON GROWTH
Pergolide to be applied in treatment of eye diseases connected with increased level of vascular endothelial growth factor (VEGF) and the pergolid-containing pharmaceutical composition